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Toward Better Stratification
of Patients With
Left Main Disease
Value of Clinical and Angiographic-Derived
Risk Scores*
Robert J. Applegate, MD
Winston-Salem, North Carolina
Predicting who will benefit from coronary revascularization
and whether percutaneous coronary intervention (PCI) or
coronary artery bypass graft (CABG) would be most bene-
ficial has been the subject of long-standing interest. The
American College of Cardiology/American Heart Associa-
tion coronary artery lesion classification was developed to
help identify high-risk lesions in patients undergoing bal-
loon angioplasty, at a time when balloon angioplasty was
indicated for discrete single lesions (1). Since that time, PCI
therapy has evolved, and the choice of PCI or CABG in
patients with more advanced coronary artery disease (CAD)
is more challenging. Although the original American Col-
lege of Cardiology/American Heart Association lesion clas-
sification was useful in guiding PCI therapy, its use in the
stent era and in more complex CAD has been problematic.
Moreover, PCI and CABG have been compared in clinical
trials with ever-increasing complexity of CAD; however,
patients with left main CAD were excluded from almost all
the contemporary comparative trials of CABG and PCI.
See page 287
The SYNTAX (Synergy between Percutaneous Coronary
intervention with TAXUS and Cardiac Surgery) trial was
the first randomized clinical trial to compare clinical out-
comes in patients with multivessel and left main CAD (2).
In the SYNTAX study, the SYNTAX score (based on 10
angiographic characteristics) provided powerful discrimina-
tion of clinical outcomes in all patients undergoing revas-
cularization (3). This score represents the most comprehen-
sive anatomic characterization of CAD to date and has
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onoraria from Abbott Vascular and St. Jude Medical.become the subject of intense clinical investigation. Patients
with a low SYNTAX score had low rates of nonfatal
myocardial infarction or death during study follow-up; and
patients with the highest tertile of SYNTAX score had the
worst clinical outcomes at study end. A post hoc evaluation
of the SYNTAX trial by the study investigators revealed
that the SYNTAX score was as predictive or had a more
predictive value than the EuroSCORE (European System
for Cardiac Operative Risk Evaluation), a risk scoring system
based on baseline clinical characteristics (4). That a risk
score based on angiographic characteristics alone was more
predictive of clinical outcomes than one based on well-
established clinical characteristics has surprised many and
spurred interest in evaluating the SYNTAX score in popu-
lations beyond the SYNTAX trial itself (4,5).
In this issue of JACC: Cardiovascular Interventions, Ca-
podanno et al. (6) provide the results of a retrospective
evaluation of the SYNTAX score combined with clinical
variables to predict mortality and major adverse cardiac
events at 2 years, in a registry of patients undergoing PCI or
CABG of unprotected left main lesions. These investigators
assessed 2 risk scores combining both angiographic and
clinical characteristics: the global risk classification, using
both the SYNTAX and EuroSCORE to create tertiles of
low- to high-risk; (7) and the clinical SYNTAX score, derived
by multiplying the SYNTAX score by the age, creatinine,
ejection fraction (ACEF) score [(age/ejection fraction)  1,
if for serum creatinine2.0 mg/dl] (8). These scores as well
as the individual angiographic and clinical scores were
compared for performance with 2 metrics: calibration and
discrimination. Calibration is the degree of correlation
between the estimated probability of an outcome as deter-
mined by the score model and the actual outcomes, mea-
sured by the Hosmer-Lemeshow test. Discrimination is the
probability that the score will assign a higher probability of
risk to patients who have events than those who do not,
measured by the area under the receiver-operator curve.
Distilling multiple results and comparisons from this regis-
try, the authors concluded that the global risk classification
score had the overall best calibration and discrimination of
the various scores in the PCI patients, whereas the ACEF
score provided the best overall performance in the CABG
patients. Interestingly, only a high SYNTAX score (32)
was able to identify a better outcome with 1 revasculariza-
tion strategy compared with the other (in this case CABG
vs. PCI) among all the scores evaluated.
The findings by Capodanno et al. (6) contribute to the
rapidly growing evidence base evaluating risk models in
patients undergoing revascularization with either PCI or
CABG for patients with extensive CAD. There are only
limited validations of risk scores in the population of
patients with left main and 3-vessel CAD. Moreover, the
SYNTAX score itself was proposed without validation (al-
though based on thoughtful combination of existing risk
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299models at the time) (3). Thus, these kinds of data are much
needed. The use of this information for guiding patient care
in patients with complex CAD, however, might be chal-
lenging for several reasons. First, the observations from this
study rest on the clinical outcomes of interventionalists and
surgeons performing PCI and CABG at 2 institutions. The
mortality and major adverse cardiac event rates after these
procedures constitute an integral element in the calibration
and discrimination values determined in their study. Thus,
they would be broadly applicable to other practices only if
the PCI and CABG outcomes achieved were similar to
those obtained in this study. Second, most physicians perform-
ing PCI and CABG are not accustomed to routinely
evaluating risk scores such as reported by Capodanno et al.
(6) before their procedures. Moreover, use of metrics such as
calibration and discrimination in assessing the performance
of risk models is not intuitive or widely understood by
clinicians. Clinicians will need extensive education in both
the derivation of these more complex risk models as well as
the ability to thoughtfully distinguish the most useful of
these models in tailoring therapy. Finally, there are no
studies prospectively comparing clinical outcomes after PCI
versus CABG in patients selected solely on a risk score.
Ironically, use of a risk score as an inclusion criterion in a
randomized clinical trial or to guide choice of PCI versus
CABG in practice might ultimately weaken the predictive
value of the risk score if both PCI and CABG are truly
comparable therapies for that specific risk group.
In the end, it seems clear that we are moving into an era
where a more sophisticated evaluation of the benefits and
risks of revascularization with PCI and CABG is going to
be expected before these procedures are performed. Patients
are becoming more sophisticated and expect the “best”
outcome as well as that their physicians are current with
practice standards. The use of appropriateness criteria for
revascularization procedures (9) will be gaining tremendous
momentum with recent allegations of use of PCI (stents) in
patients without severe CAD. Finally, scorecarding of out-
comes is proliferating and is being widely used by health
care systems to tout their skills and abilities. As physicians
are drawn into this type of discussion, it is clear that
inappropriate risk stratification is the number one issue
raised in defense of less-than-optimal results. For all of
these reasons, we will be using more sophisticated risk score
systems in our practice. The challenge is to make them moreuser-friendly and hope that they continue to enhance rather
than delay appropriate treatment.
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